Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Assistance Publique - Hôpitaux de Paris
Washington University School of Medicine
Prescient Therapeutics, Ltd.
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
University of Pittsburgh
Fondazione Italiana Linfomi - ETS
Fondazione Italiana Linfomi - ETS
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
City of Hope Medical Center
Icahn School of Medicine at Mount Sinai
Barbara Ann Karmanos Cancer Institute
Stanford University
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Washington University School of Medicine
Lund University Hospital
University College, London
Assistance Publique - Hôpitaux de Paris
Kyowa Kirin Co., Ltd.
4SC AG
Emory University
Peking University First Hospital
Columbia University
Kyowa Kirin Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
University of Nebraska
National Cancer Institute (NCI)
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Genmab
Stanford University
Genmab